Comprehensive Study Guide to Acute Coronary Syndromes: Epidemiology, Diagnosis, and Management

Epidemiology and Global Impact of Cardiovascular Disease

Cardiovascular disease (CVD) represents the primary cause of mortality and morbidity on a global scale. A significant portion of this global health burden is concentrated in low- and middle-income countries. Acute coronary syndrome (ACS) frequently serves as the inaugural clinical manifestation of cardiovascular disease. According to the 2023 ESC Guidelines, there were approximately 5.8×1065.8 \times 10^6 new cases of ischaemic heart disease reported across 57 European Society of Cardiology (ESC) countries in 2019. Within these nations, CVD remains the leading cause of death, accounting for nearly 2.2×1062.2 \times 10^6 deaths among females and over 1.9×1061.9 \times 10^6 deaths among males. Specifically, ischaemic heart disease is the most prevalent cause of CVD-related mortality, representing 38%38\% of all CVD deaths in females and 44%44\% in males.

Pathogenesis and Atherogenesis Progressive Stages

The development of acute coronary syndromes is rooted in the process of atherogenesis within the arterial walls. This progression is characterized by six distinct stages. (1) The process begin with a normal artery, which transitions to (2) the accumulation of extracellular lipids. This progresses to (3) the fibrofatty stage, followed by (4) the expression of procoagulants and the subsequent weakening of the fibrous cap. Acute coronary syndrome specifically develops during (5) the disruption of the fibrous cap, which acts as the primary stimulus for thrombogenesis. Finally, (6) thrombus resorption may occur, often followed by collagen accumulation and the growth of smooth muscle cells. The resulting thrombus formation restricts blood flow in the affected coronary artery, leading to the clinical experience of ischemic chest pain. Ischemic heart disease clinically manifests as either chronic stable angina or ACS, the latter of which encompasses ST-segment elevation myocardial infarction (STEMI) and non-ST elevation acute coronary syndromes (NSTE-ACS).

Pathophysiological Mechanisms of NSTE-ACS and STEMI

The pathogenesis of NSTE-ACS, which includes unstable angina (UA) and non-ST-segment elevation MI (NSTEMI), involves five primary processes that may operate individually or in combination. These include the disruption of an unstable atheromatous plaque, the erosion of an atheromatous plaque, coronary arterial vasoconstriction, gradual intraluminal narrowing of an epicardial coronary artery due to progressive atherosclerosis or post-PCI restenosis, and oxygen supply-demand mismatch. In UA and NSTEMI, plaque rupture and coronary thrombosis compromise blood flow, though the infarct-related artery is generally not completely occluded for a prolonged period. The thrombi in these cases are typically grayish-white and platelet-rich. In contrast, STEMI involves complete occlusion of the artery by reddish, fibrin-rich thrombi containing platelets and red blood cells. Sudden death can occur as a severe outcome of these processes. Plaque rupture of a necrotic core with an overlying thin cap is the most frequent pathophysiology, occurring in 70%−80%70\%-80\% of cases. Plaque erosion, where the thrombus is in direct contact with an intimal plaque rich in smooth muscle cells and proteoglycan matrix, occurs in approximately 25%25\% of cases. The least common morphology (<5%−10%<5\% - 10\%) is the calcified nodule, characterized by a heavily calcified plaque surrounded by fibrosis, which is more common in older men.

Clinical Presentation and Diagnostic Symptoms

Acute chest discomfort is the leading symptom prompting consideration of an ACS diagnosis. This discomfort may be described by patients as pain, pressure, tightness, heaviness, or burning. Approximately 80%80\% of both men and women with ACS present with chest pain or pressure. Associated symptoms occurring commonly in both genders include diaphoresis, indigestion or epigastric pain, and pain in the shoulder or arm. Some symptoms are statistically more frequent in women, including dizziness, syncope, nausea, vomiting, jaw or neck pain, shortness of breath, palpitations, fatigue, and pain located between the shoulder blades. Classic symptoms associated with a heart attack include "crushing" chest pain, sweating, pallor, and difficulty breathing. While the usual distribution of pain involves the central chest and left arm, less common sites include the right side, jaw, epigastrium, and back. The likelihood of ACS is increased by factors such as older age, male sex, family history of coronary artery disease (CAD), diabetes, hyperlipidaemia, smoking, hypertension, renal dysfunction, previous CAD, and peripheral or carotid artery disease. ACS can be exacerbated by conditions like anaemia, infection, fever, hypertensive crisis, emotional stress, and metabolic or endocrine disorders like thyroid disease.

Differential Diagnosis for Acute Chest Pain

When evaluating a patient for ACS, several differential diagnoses must be considered across multiple systems. Cardiac causes include myocarditis, pericarditis, cardiomyopathies, tachyarrhythmias, acute heart failure, Takotsubo syndrome, coronary spasm, cardiac trauma, and symptomatic aortic valve stenosis. Vascular considerations include pulmonary embolism, aortic dissection, symptomatic aortic aneurysm, stroke, and hypertensive emergencies. Pulmonary causes include tension pneumothorax, bronchitis, pneumonia, and pleuritis. Gastrointestinal causes include oesophagitis, reflux, esophageal spasm, peptic ulcers, gastritis, pancreatitis, and cholecystitis. Orthopaedic and musculoskeletal causes include chest trauma, muscle injury, costochondritis, and cervical spine pathologies. Other potential causes include anxiety disorders, herpes zoster, anaemia, and exhaustion.

Initial Evaluation and Diagnostic Tools

The diagnostic process for ACS is recommended to be based on a combination of clinical history, symptoms, vital signs, electrocardiogram (ECG), and high-sensitivity cardiac troponin (hs-cTn). During the physical examination, while often normal, clinicians may find audible third (S3S3) or fourth (S4S4) heart sounds or pulmonary rales in patients with large territories of ischemia. Findings like hypotension, cool pale skin, and sinus tachycardia are more common in STEMI. The 12-lead ECG is the first-line diagnostic tool and must be obtained and interpreted within 10 min10\,\text{min} of first medical contact (FMC). Patients are differentiated into two working diagnoses based on the ECG: those with persistent ST-segment elevation (STEMI) and those without (NSTE-ACS). Transthoracic echocardiography (TTE) is recommended for patients in cardiogenic shock or with suspected mechanical complications.

ECG Patterns and Localization of Infarction

In NSTE-ACS, the most common abnormalities are ST-segment depression and T-wave inversion. Specific NSTEMI ECG criteria include: (a) Isolated T-wave inversion >1 mm>1\,\text{mm} in ≥5\ge 5 leads including I, II, aVL, and V2-V6; (b) ST-segment depression of ≥0.5 mm\ge 0.5\,\text{mm} in V2-V3 or ≥1 mm\ge 1\,\text{mm} in other leads; (c) Transient ST-elevation lasting <20 min<20\,\text{min}; (d) De Winter ST-T sign, featuring 1−3 mm1-3\,\text{mm} upsloping ST-depression at the J-point in V1-V6 continuing into tall, positive T-waves; and (e) Wellens sign, where Type A shows biphasic T-waves and Type B shows deeply inverted T-waves in V2-V3, indicating proximal LAD occlusion. For STEMI, criteria include new ST-elevation at the J-point in ≥2\ge 2 contiguous leads of >2.5 mm>2.5\,\text{mm} in men <40<40 years, >2 mm>2\,\text{mm} in men ≥40\ge 40 years, or ≥1.5 mm\ge 1.5\,\text{mm} in women (leads V2-V3), and/ge 1 mm1\,\text{mm} in other leads. Infarction localization is categorized as Septal (V1-V2), Anterior (V3-V4), Lateral (I, aVL, V5-V6), and Inferior (II, III, aVF). The aVR lead is used for diagnosing left main artery (LMA) stenosis.

Cardiac Biomarkers and Universal Definition of Myocardial Infarction

Cardiac-specific troponins I (cTnI) and T (cTnT) are the markers of choice for identifying myocardial injury. High-sensitivity (hs-cTn) assays are recommended for their high negative predictive value and ability to reduce the "troponin-blind" interval. Acute Myocardial Infarction is defined as acute myocardial injury (a rise and/or fall of cTn with at least one value above the 99th99\text{th} percentile upper reference limit) accompanied by clinical evidence of ischaemia, such as symptoms, new ECG changes, pathological Q waves, imaging evidence of loss of viable myocardium, or identification of a coronary thrombus. The ESC recommends an algorithmic approach with serial measurements at 0 h/1 h0\,\text{h}/1\,\text{h} or 0 h/2 h0\,\text{h}/2\,\text{h} to rule in or rule out NSTEMI. Type 1 MI is associated with plaque rupture or erosion with thrombus. Type 2 MI is myocardial injury related to oxygen supply-demand imbalance (e.g., atherosclerosis, vasospasm, microvascular dysfunction, or dissection) without acute atherothrombosis. Histological cell death begins within 20 min20\,\text{min} of ischaemia, and complete necrosis requires at least 2−4 h2-4\,\text{h}.

Risk Stratification and Time-to-Invasive Strategy

Risk assessment for ACS patients should utilize established risk scores like the GRACE (Global Registry of Acute Coronary Events) score. High-risk patients are defined by a GRACE score >140>140, recurrent ischemia, dynamic ST changes, or elevated troponins, with a 3030-day mortality/MI risk of 12%−30%12\%-30\%. Low-risk patients (GRACE <109<109) have a risk of <2%<2\%. Management timing is based on risk: (1) Immediate invasive strategy (<2 h<2\,\text{h}) is for very-high-risk features like hemodynamic instability, cardiogenic shock, refractory chest pain, life-threatening arrhythmias, or mechanical complications. (2) Early invasive strategy (<24 h<24\,\text{h}) is for high-risk patients with a confirmed NSTEMI diagnosis, GRACE score >140>140, or dynamic ST/T changes. (3) Inpatient invasive strategy is for those without very-high or high-risk features but with a clinical suspicion of ACS. (4) Selective invasive strategy is for non-high-risk patients.

Reperfusion Therapy for STEMI

All patients with a working diagnosis of STEMI and symptoms of ischaemia for ≤12 h\le 12\,\text{h} duration must undergo immediate reperfusion therapy. Primary Percutaneous Coronary Intervention (PPCI) is the preferred strategy if the anticipated time from diagnosis to PCI is <120 min<120\,\text{min}. If timely PPCI cannot be performed, fibrinolytic therapy is recommended within 12 h12\,\text{h} of symptom onset for patients without contraindications. Following fibrinolysis, all patients should be transferred to a PCI-capable center. Rescue PCI is recommended if fibrinolysis fails (defined as <50%<50\% ST-segment resolution within 60−90 min60-90\,\text{min}). Contraindications for fibrinolysis include previous intracranial hemorrhage, ischemic stroke within 66 months, CNS damage/neoplasms, major trauma or surgery within the past month, gastrointestinal bleeding within the past month, known bleeding disorders, aortic dissection, and non-compressible punctures within 24 h24\,\text{h}.

Acute Pharmacological Management

Initial treatment for STEMI often follows the MONA protocol: Morphine (5−15 min5-15\,\text{min}, Class I), Oxygen (if sat <90%<90\%, Class I), Nitroglycerin (0.4 mg0.4\,\text{mg} sublingual every 5 min5\,\text{min} up to three times), and Aspirin. Antiplatelet therapy includes a loading dose of Aspirin (162−325 mg162-325\,\text{mg}, then 75−162 mg75-162\,\text{mg} daily) and a P2Y12 inhibitor. P2Y12 choices include Ticagrelor (180 mg180\,\text{mg} loading, then 90 mg90\,\text{mg} twice daily), Prasugrel (60 mg60\,\text{mg} loading, then 10 mg10\,\text{mg} daily), or Clopidogrel (300−600 mg300-600\,\text{mg} loading, then 75 mg75\,\text{mg} daily). Prasugrel and Ticagrelor are preferred over Clopidogrel. Anticoagulation options include Low Molecular Weight Heparin (e.g., enoxaparin 1 mg/kg1\,\text{mg/kg} every 12 h12\,\text{h}) or Unfractionated Heparin (UFH) targeting an aPTT of 2−2.52-2.5 times baseline. Additional acute treatments include intravenous nitrates for pain, beta-blockers, ACE inhibitors, and statins to improve prognosis.

Long-Term Management, Secondary Prevention, and Rehabilitation

Long-term management focuses on cardioprotective medications and lifestyle modifications. Standard-of-care includes Dual Antiplatelet Therapy (DAPT) for 1212 months, high-dose statins (aiming for LDL-C <1.4 mmol/L<1.4\,\text{mmol/L} or a 50%50\% reduction), and ACE inhibitors/ARBs for patients with LVEF ≤40%\le 40\%, HF, diabetes, or hypertension. Beta-blockers are recommended particularly if LVEF ≤40%\le 40\%. If LDL goals are not met with statins, ezetimibe should be added, followed by PCSK9 inhibitors. For patients with recurrent events within 22 years, an LDL-C goal of <1.0 mmol/L<1.0\,\text{mmol/L} may be considered. Lifestyle management includes total tobacco cessation, a Mediterranean-style diet, alcohol restriction, and regular aerobic and resistance exercise. All patients should participate in structured cardiac rehabilitation and receive annual influenza vaccinations. For patients with persistent LVEF ≤40%\le 40\% despite optimal therapy, a repeat evaluation 6−126-12 weeks post-ACS is recommended to assess the need for an implantable cardioverter-defibrillator (ICD) for sudden cardiac death prevention. Low-dose colchicine (0.5 mg0.5\,\text{mg} daily) may be considered for additional anti-inflammatory benefit.